Next-generation weight-management drugs face a simple challenge: effectiveness must be matched by tolerability.
In a recent clinical study, the company’s patented oral delivery platform reduced adverse events by up to 50%.
With two promising drug candidates in development, Medicus Pharma is targeting significant market gaps in prostate cancer and skin cancer treatment.
Medicus Pharma is introducing a groundbreaking therapy to prevent relapse in men suffering from acute urinary retention due to enlarged prostate.
Medicus Pharma is developing a cardio-sparing hormone therapy for prostate cancer patients—targeting both cancer and heart safety.
